Education
About Us
Working with TipRanks
Follow Us
Aptose Biosciences (APTOF)
OTHER OTC:APTOF
Total Valuation
Aptose Biosciences has a market cap or net worth of $3.62M. The enterprise value is $16.69M.
Market Cap$3.62M
Enterprise Value$16.69M
Share Statistics
Aptose Biosciences has 2,552,429 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding2,552,429
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Aptose Biosciences’s return on equity (ROE) is 5.60 and return on invested capital (ROIC) is -430.73%.
Return on Equity (ROE)5.60
Return on Assets (ROA)-2.51
Return on Invested Capital (ROIC)-430.73%
Return on Capital Employed (ROCE)-4.63
Revenue Per Employee0.00
Profits Per Employee-1.96M
Employee Count13
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Aptose Biosciences is ―. Aptose Biosciences’s PEG ratio is 0.06.
PE Ratio―
PS Ratio0.00
PB Ratio-34.40
Price to Fair Value-34.40
Price to FCF-4.34
Price to Operating Cash Flow-0.54
PEG Ratio0.06
Income Statement
In the last 12 months, Aptose Biosciences had revenue of 0.00 and earned -25.43M in profits. Earnings per share was -0.04.
Revenue0.00
Gross Profit0.00
Operating Income-26.26M
Pretax Income-25.43M
Net Income-25.43M
EBITDA-26.23M
Earnings Per Share (EPS)-0.04
Cash Flow
In the last 12 months, operating cash flow was -24.21M and capital expenditures -5.00K, giving a free cash flow of -24.21M billion.
Operating Cash Flow-24.21M
Free Cash Flow-24.21M
Free Cash Flow per Share-9.49
Dividends & Yields
Aptose Biosciences pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.07
52-Week Price Change-71.13%
50-Day Moving Average1.41
200-Day Moving Average1.72
Relative Strength Index (RSI)63.55
Average Volume (3m)2.60K
Important Dates
Aptose Biosciences upcoming earnings date is Mar 24, 2026, TBA (Confirmed).
Last Earnings DateNov 13, 2025
Next Earnings DateMar 24, 2026
Ex-Dividend Date―
Financial Position
Aptose Biosciences as a current ratio of 2.14, with Debt / Equity ratio of -1.57%
Current Ratio2.14
Quick Ratio2.14
Debt to Market Cap0.06
Net Debt to EBITDA-0.17
Interest Coverage Ratio126.85
Taxes
In the past 12 months, Aptose Biosciences has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Aptose Biosciences EV to EBITDA ratio is -6.13, with an EV/FCF ratio of -4.47.
EV to Sales0.00
EV to EBITDA-6.13
EV to Free Cash Flow-4.47
EV to Operating Cash Flow-4.47
Balance Sheet
Aptose Biosciences has $613.00K in cash and marketable securities with $19.02M in debt, giving a net cash position of -$18.40M billion.
Cash & Marketable Securities$613.00K
Total Debt$19.02M
Net Cash-$18.40M
Net Cash Per Share-$7.21
Tangible Book Value Per Share>-$0.01
Margins
Gross margin is 50.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin50.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Aptose Biosciences is $1.75, which is 11.43% higher than the current price. The consensus rating is Hold
Price Target$1.75
Price Target Upside6.71% Upside
Analyst ConsensusHold
Analyst Count1
Revenue Growth Forecast―
EPS Growth Forecast―